Coeptis Therapeutics, Inc.
COEPNASDAQHealthcare
$16.40
+$0.00(+0.00%)
Market Cap$57626976
P/E Ratio—
52W High$21.41
52W Low$6.8
Coeptis Therapeutics, Inc. (COEP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · COEP · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.36M | $0.00M | $0.00M | $0.00M | $0.07M |
| Cost of Revenue | $0.18M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $1.18M | $0.00M | $0.00M | $0.00M | $0.07M |
| Gross Margin %(computed) | 86.75% | — | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $1.28M | $2.33M | $6.67M | $0.02M | $0.00M |
| G&A Expenses | $11.84M | $6.72M | $13.82M | $34.17M | $14.12M |
| Total Operating Expenses | $14.23M | $10.05M | $21.49M | $34.20M | $14.12M |
| Operating Income | ($13.04M) | ($10.05M) | ($21.49M) | ($34.20M) | ($14.05M) |
| Operating Margin %(computed) | -956.94% | — | — | — | — |
| Interest Income | $0.12M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.64M | $0.40M | $0.11M | $0.22M | $0.19M |
| Income Before Tax | ($12.28M) | ($10.88M) | ($21.27M) | ($37.57M) | ($13.45M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($11.92M) | ($10.68M) | ($21.27M) | ($37.57M) | ($13.45M) |
| Net Margin %(computed) | -874.29% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.81 | $-5.65 | $-0.83 | $-2.87 | $-13.16 |
| Wtd Avg Shares | 4.23M | 1.93M | 25.69M | 14.30M | 1.02M |
| EBITDA | ($10.41M) | ($9.38M) | ($20.12M) | ($36.35M) | ($12.81M) |
| EBITDA Margin %(computed) | -763.89% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Coeptis Therapeutics, Inc. data
About Coeptis Therapeutics, Inc. (COEP) Income Statement
Coeptis Therapeutics, Inc. (COEP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, COEP reported revenue of $0.00B, gross profit of $0.00B (gross margin 86.75%), and net income of ($0.01B) — a net profit margin of -874.29%.
Frequently asked questions
COEP · 4 questionsCoeptis Therapeutics, Inc. (COEP) reported revenue of $0.00B for 2025, up —% year-over-year.
COEP revenueCOEP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09